Propanc Biopharma (PPCB) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

—

Revenue (quarter)

—

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

—

Gross margin

—

Net income (trailing twelve months)

—

Net income (quarter)

−$4.6M

Net income growth (year over year)

−12.32%

Net margin

—

Return on equity

−169.86%

EPS (trailing twelve months)

−$17.62

Book value per share

$2.84

P/E (trailing twelve months)

—

Price to book

0.46

Debt to assets

26.43%

Payout ratio

—

Dividend yield

—

Company profile

Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.

• How do I buy stock in Propanc Biopharma (PPCB)?

  PPCB trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.